Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Studies have shown that utilising a PARP inhibitor in the management of patients with metastatic…
Browsing: PARP inhibitor
Aggressive childhood cancer could be treated by combining DNA-damage targeting drugs
An aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently…
ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation
Maintenance therapy with olaparib extended overall survival by nearly 13 months (12.9) compared with placebo…
AACR 2020: Study shows immunotherapy prior to surgery may help destroy high-risk breast cancer
A study led by Yale Cancer Center (YCC), USA, researchers shows women with high-risk HER2-negative…
PARP inhibitor drugs can be ‘tuned’ for better killing of tumour cells
A prospective “PARP inhibitor” drug that has struggled to show effectiveness in clinical trials against…
ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more…
Ovarian cancer drug niraparib maintains remission and extends time without symptoms
Findings from a recent clinical trial presented today at the Society of Gynecologic Oncology’s 50th…
First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA breast cancer patients
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers…
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including…
ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to…